METHODS TO PRODUCE A HUMAN PLASMA-DERIVED IGG PREPARATION ENRICHED IN BRAIN DISEASE-RELATED NATURAL IGGS
The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti- , anti-RAGE, and anti-α-synuclein antibodies). Advantageously, the methods provided do not a...
Saved in:
Main Authors | , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
18.09.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti- , anti-RAGE, and anti-α-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-brain disease related protein antibodies (e.g., anti- , anti-RAGE, and anti-α-synuclein antibodies), as also provided here. Methods for the treatment of brain diseases and disorders by administration of plasma-derived IgG compositions highly enriched for anti- brain disease related protein antibodies (e.g., anti- , anti-RAGE, and anti-α-synuclein antibodies), are also provided.
La présente invention concerne, entre autres, des procédés de fabrication de compositions d'immunoglobulines G d'origine plasmatique hautement enrichies en anticorps protéiques associés à une maladie du cerveau (par ex., des anticorps anti- , anti-RAGE, et anti-α-synucléine). De manière avantageuse, les procédés selon l'invention n'affectent pas les processus de fabrication ou les capacités de production d'agents thérapeutiques à base d'IgG d'origine plasmatique. L'invention concerne également des compositions d'IgG d'origine plasmatique qui sont hautement enrichies en anticorps protéiques associés à une maladie du cerveau (par ex., des anticorps anti- , anti-RAGE, et anti-α-synucléine). L'invention concerne également des méthodes pour le traitement de maladies et de troubles du cerveau par administration de compositions d'IgG d'origine plasmatique hautement enrichies en anticorps protéiques associés à une maladie du cerveau (par ex., des anticorps anti- , anti-RAGE, et anti-α-synucléine). |
---|---|
Bibliography: | Application Number: WO2014US28953 |